Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 175

  • 3 924 clinical trials
  • 1 545 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 924 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 924 clinical trials

Gastric cancer

Not recruiting

Study of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Ovarian cancer

Not recruiting

Study of Saruparib in Patients with Advanced or Recurrent Ovarian Cancer to Assess Safety and Effectiveness

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Saruparib
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma

Not recruiting

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Fondation Franc.Cancerologie Digestive

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Bladder transitional cell carcinoma

Not recruiting

Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Immunitybio Inc.

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Zelenectide Pevedotin in Adults with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer with NECTIN4 Amplification

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Bicycletx Limited

Haematological malignancy+1

Not recruiting

Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Plasma cell myeloma refractory

Not recruiting

Comparing CT-P44 and Darzalex Faspro with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Celltrion Inc.

Gastric cancer+3

Not recruiting

Study of AZD4360 safety and effectiveness in adults with advanced solid tumors including gastric, gastroesophageal junction, biliary tract cancer and pancreatic cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:AZD4360
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of DCC-3084 alone and with other cancer drugs in patients with advanced solid tumors driven by the MAPK pathway

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:DCC-3084
  • Sponsor:Deciphera Pharmaceuticals Inc.

Colorectal cancer

Not recruiting

A study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Non-small cell lung cancer+5

Not recruiting

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:AIO-Studien gGmbH

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Infliximab65 clinical trialsVincristine Sulfate55 clinical trialsAbemaciclib45 clinical trialsIbrutinib43 clinical trialsTrifluridine31 clinical trialsAvelumab30 clinical trialsApalutamide27 clinical trialsAmivantamab25 clinical trialsZanubrutinib24 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.